Protective Effect of SARS-CoV-2 Preventive Measures Against ESKAPE and Escherichia Coli Infections
Overview
Authors
Affiliations
Background/objectives: We investigated whether behavioral precautions adopted during Coronavirus disease (COVID-19) pandemic also influenced the spreading and multidrug resistance (MDR) of ESKAPEEc (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii [AB], Pseudomonas aeruginosa, Enterobacter spp and Escherichia Coli, [EC]) among Intensive Care Unit (ICU) patients.
Subjects/methods: We performed a single-center retrospective study in adult patients admitted to our COVID-19-free surgical ICU. Only patients staying in ICU for more than 48 hours were included. The ESKAPEEc infections recorded during the COVID-19 period (June 1, 2020 - February 28, 2021) and in the corresponding pre-pandemic period (June 1, 2019 - February 28, 2020) were compared. An interrupted time series analysis was performed to rule out possible confounders.
Results: Overall, 173 patients in the COVID-19 period and 132 in the pre-COVID-19 period were investigated. The ESKAPEEc infections were documented in 23 (13.3%) and 35 (26.5%) patients in the pandemic and the pre-pandemic periods, respectively (p = 0.005). Demographics, diagnosis, comorbidities, type of surgery, Simplified Acute Physiology Score II, length of mechanical ventilation, hospital and ICU length of stay, ICU death rate, and 28-day hospital mortality were similar in the two groups. In comparison with the pre-pandemic period, no AB was recorded during COVID-19 period, (p = 0.017), while extended-spectrum beta-lactamase-producing EC infections significantly decreased (p = 0.017). Overall, the ESKAPEEc isolates during pandemic less frequently exhibited multidrug-resistant (p = 0.014).
Conclusions: These findings suggest that a robust adherence to hygiene measures together with human contact restrictions in a COVID-19 free ICU might also restrain the transmission of ESKAPEEc pathogens.
Baum J, Dorre A, Reichert F, Noll I, Feig M, Eckmanns T BMC Microbiol. 2025; 25(1):51.
PMID: 39875841 PMC: 11773696. DOI: 10.1186/s12866-024-03723-5.
Dabaja-Younis H, Silman Z, Tarabeia J, Hussein K BMC Infect Dis. 2024; 24(1):1364.
PMID: 39609675 PMC: 11605931. DOI: 10.1186/s12879-024-09240-0.
de Souza P, Santos M, Miranda R, Costa L, da Silva R, de Miranda C Life (Basel). 2024; 14(9).
PMID: 39337864 PMC: 11433527. DOI: 10.3390/life14091079.
A scoping review of bacterial resistance among inpatients amidst the COVID-19 pandemic.
Reffat N, Schwei R, Griffin M, Pop-Vicas A, Schulz L, Pulia M J Glob Antimicrob Resist. 2024; 38:49-65.
PMID: 38789083 PMC: 11392638. DOI: 10.1016/j.jgar.2024.05.010.
Plant-Origin Components: New Players to Combat Antibiotic Resistance in .
Luna-Pineda V, Rodriguez-Martinez G, Salazar-Garcia M, Romo-Castillo M Int J Mol Sci. 2024; 25(4).
PMID: 38396811 PMC: 10888558. DOI: 10.3390/ijms25042134.